Intestinal Cell News Volume 7.31 | Aug 20 2021

    0
    37







    2021-08-20 | ICN 7.31


    Intestinal Cell News by STEMCELL Technologies
    Vol. 7.31 – 20 August, 2021
    TOP STORY

    Dietary Fructose Improves Intestinal Cell Survival and Nutrient Absorption

    Researchers showed that dietary fructose improved the survival of intestinal cells and increased intestinal villus length in several mouse models. In hypoxic intestinal cells, fructose 1-phosphate inhibited the M2 isoform of pyruvate kinase to promote cell survival.
    [Nature]

    AbstractPress Release

    Culture Mouse Intestinal Organoids With On-Demand Training. Learn More
    PUBLICATIONSRanked by the impact factor of the journal

    Molecular Phenotyping Reveals the Identity of Barrett’s Esophagus and Its Malignant Transition

    A combination of single-cell transcriptomic profiling, in silico lineage tracing from methylation, open chromatin and somatic mutation analyses, and functional studies in organoid models showed that Barrett’s esophagus originated from gastric cardia through c-MYC and HNF4A-driven transcriptional programs.
    [Science]

    AbstractPress Release

    Dysregulation of ILC3s Unleashes Progression and Immunotherapy Resistance in Colon Cancer

    Scientists identified that colorectal cancer manifested with altered ILC3s that were characterized by reduced frequencies, increased plasticity, and an imbalance with T cells.
    [Cell]

    AbstractGraphical Abstract

    Adipose Stem Cell Niche Reprograms the Colorectal Cancer Stem Cell Metastatic Machinery

    Visceral adipose-derived factors promoted vasculogenesis and the onset of metastatic dissemination by activation of STAT3, which inhibited miR-200a and enhanced ZEB2 expression, effectively reprogramming colorectal cancer cells into a highly metastatic phenotype.
    [Nature Communications]

    Full Article

    ITLN1 Inhibits Tumor Neovascularization and Myeloid Derived Suppressor Cells Accumulation in Colorectal Carcinoma

    Investigators explored the inhibitory role of ITLN1 in the tumor-permissive microenvironment that existed during the first occurrence and subsequent development of colorectal carcinoma.
    [Oncogene]

    Abstract

    Mutant APC Promotes Tumor Immune Evasion via PD-L1 in Colorectal Cancer

    The authors demonstrated that mutations in the adenomatous polyposis coli (APC) gene led to colonic epithelial cell resistance to CD8+ T cell cytotoxicity by induction of PD-L1 expression.
    [Oncogene]

    Abstract

    The IL-33-ILC2 Pathway Protects from Amebic Colitis

    Through transcriptomics analysis, researchers observed that Entamoeba histolytica infection was associated with increased expression of IL-33 mRNA in both the human and murine colon.
    [Mucosal Immunology]

    Full Article

    Chimeric Virus-Like Particles (VLPs) Designed from Shrimp Nodavirus (MrNV) Capsid Protein Specifically Target EGFR-Positive Human Colorectal Cancer Cells

    Scientists created three different types of chimeric MrNV VLPs that had specificity toward the epidermal growth factor receptor (EGFR), a cancer cell biomarker, by incorporating the EGFR-specific GE11 peptide at three different locations within the host cell recognition site of the capsid.
    [Scientific Reports]

    Full Article

    Characterization of an In Vitro 3D Intestinal Organoid Model by Using Massive RNAseq-Based Transcriptome Profiling

    Investigators showed a comprehensive transcriptome-wide characterization of mouse gut organoids derived from different intestinal compartments and from mice of different gender and age.
    [Scientific Reports]

    Full Article

    Colorectal Cancer Cell Differentiation Is Dependent on the Repression of Aerobic Glycolysis by NDRG2-TXNIP Axis

    Researchers demonstrated that NDRG2 promoted the differentiation of colorectal cancers, potentially through the inhibition of aerobic glycolysis via TXNIP induction.
    [Digestive Diseases and Sciences]

    Abstract

    Evaluating CRISPR-Based Prime Editing for Cancer Modeling and CFTR Repair in Organoids

    The authors explored the use of prime editing in human organoids. Common TP53 mutations could be correctly modeled in human adult stem cell–derived colonic organoids with efficiencies up to 25% and up to 97% in hepatocyte organoids.
    [Life Science Alliance]

    Full ArticlePress Release

    The Effect and Mechanism of Erianin on the Reversal of Oxaliplatin Resistance in Human Colon Cancer Cells

    Scientists treated human colon cancer oxaliplatin-resistant cells with oxaliplatin combined with natural product erianin, evaluated the impact of erianin on drug resistance, and explored the relationship between erianin- related oxaliplatin resistance and JAK2/STAT3 signaling pathway in vitro.
    [Cell Biology International]

    Abstract

    Multi-Omic Profiling of Peritoneal Metastases in Gastric Cancer Identifies Molecular Subtypes and Therapeutic Vulnerabilities

    Researchers presented a comprehensive multi-omic analysis of malignant ascitic fluid samples and their corresponding tumor cell lines from 98 patients, including whole-genome sequencing, RNA sequencing, DNA methylation and enhancer landscape.
    [Nature Cancer]

    Abstract

    Scientific resources to support your organoids research. Learn More!
    REVIEWS

    Tumor Organoids: Opportunities and Challenges to Guide Precision Medicine

    Scientists provide a critical overview of both clinical and preclinical advances using tumor organoids.
    [Cancer Cell]

    Abstract

    INDUSTRY AND POLICY NEWS

    STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services

    STEMCELL Technologies and Hubrecht Organoid Technology announced that they have signed an agreement for the use of tissue-derived organoids—including lung, intestinal, and liver organoids—for use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL.
    [STEMCELL Technologies, Inc.]

    Press Release

    Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors

    Gracell Biotechnologies, Inc. announced an exclusive license agreement with FutureGen Biopharm to develop engineered immune cell therapies targeting Claudin 18.2, a tumor-specific marker that is overexpressed in a variety of tumor tissues, including in gastric or gastroesophageal junction cancers.
    [Gracell Biotechnologies, Inc.]

    Press Release

    FEATURED EVENT

    Cell & Gene Meeting on the Mesa

    October 12 – 14, 2021
    Carlsbad, California, United States and Virtual

    > See All Events

    JOB OPPORTUNITIES

    Faculty Position – Cancer Biology and Signal Transduction

    Purdue University – West Lafayette, Indiana, United States

    Investigator – Host Immunity and Microbiome

    National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States

    Scientist – Autoimmune and Inflammatory Diseases

    Amgen – San Francisco, California, United States

    Research Assistant – Pharmacology

    The Scripps Research Institute – La Jolla, California, United States

    PhD Student – Stem Cell Biology in Intestinal Tumorigenesis

    Philipps University of Marburg – Marburg, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Intestinal Cell News Twitter